1. Serum Copeptin Levels in Adult Patients with a Migraine Attack: A Cross-Sectional Study
- Author
-
Ilker Eski, Ozgur Sogut, Ozgur Deniz Sadioglu, Sumeyye Cakmak, Huseyin Ergenc, and Onur Kaplan
- Subjects
copeptin ,migraine ,biomarker ,headache ,Medicine ,Medicine (General) ,R5-920 - Abstract
Aim:This study investigated the potential role of serum copeptin, a mediator of acute pain via sympathetic stress stimulation, as a biomarker of varying degrees of migraine-related disability. Specifically, we aimed to analyze whether the serum copeptin level can be used to differentiate migraine types (e.g., with and without aura).Methods:The study population included 80 consecutively consenting adult patients who had migraine attacks and attended the emergency department from June 2020 through November 2020, as well as 80 age- and sex-matched healthy controls. Using the Migraine Disability Assessment Scale (MIDAS), the same medical professional assessed each patient’s level of headache-related disability. Based on their MIDAS scores, the patients were separated into four groups: no disability (score 0-5; group MIDAS-I); mild disability (score 6-10; group MIDAS-II); moderate impairment (score 11-20; group MIDAS-III); and severe disability (score >20; group MIDAS-IV). There were also two categories of migraineurs: those with auras and those without auras. Upon admission, comparisons were made between the groups’ serum copeptin values.Results:In comparison to the control group, the patient group’s serum copeptin levels were noticeably higher (2113.30±206.20 vs. 1383.40±488.40; p
- Published
- 2023
- Full Text
- View/download PDF